Boston Scientific Q2 2026 Sales Growth Beat Expectations
Boston Scientific reported solid Q2 2026 sales growth, growth in all segments, and completed a $2 billion share repurchase. The adjusted EPS was ahead of guidance.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day